PAK1 mediates resistance to PI3K inhibition in lymphomas

Katherine Walsh, Matthew S. McKinney, Cassandra Love, Qingquan Liu, Alice Fan, Amee Patel, Jason Smith, Anne Beaven, Dereje D. Jima, Sandeep S. Dave

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose: The phosphoinositide 3-kinase (PI3K) pathway is known to play an active role in many malignancies. The role of PI3K inhibition in the treatment of lymphomas has not been fully delineated. We sought to identify a role for therapeutic PI3K inhibition across a range of B-cell lymphomas. Experimental Design: We selected three small molecule inhibitors to test in a panel of 60 cell lines that comprised diverse lymphoma types. We tested the selective PI3K inhibitor BKM120 and the dual PI3K/ mTOR inhibitors BEZ235 and BGT226 in these cell lines. We applied gene expression profiling to better understand the molecular mechanisms associated with responsiveness to these drugs. Results: We found that higher expression of the PAK1 gene was significantly associated with resistance to all three PI3K inhibitors. Through RNA-interference-mediated knockdown of the PAK1 gene, we showed a dramatic increase in the sensitivity to PI3K inhibition. We further tested a small-molecule inhibitor of PAK1 and found significant synergy between PI3K and PAK1 inhibition. Conclusion: Thus, we show that PI3K inhibition is broadly effective in lymphomas and PAK1 is a key modulator of resistance to PI3K inhibition.

Original languageEnglish (US)
Pages (from-to)1106-1115
Number of pages10
JournalClinical Cancer Research
Volume19
Issue number5
DOIs
StatePublished - Mar 1 2013
Externally publishedYes

Fingerprint

1-Phosphatidylinositol 4-Kinase
Lymphoma
Gene Knockdown Techniques
Cell Line
Gene Expression Profiling
B-Cell Lymphoma
RNA Interference
Research Design
Gene Expression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Walsh, K., McKinney, M. S., Love, C., Liu, Q., Fan, A., Patel, A., ... Dave, S. S. (2013). PAK1 mediates resistance to PI3K inhibition in lymphomas. Clinical Cancer Research, 19(5), 1106-1115. https://doi.org/10.1158/1078-0432.CCR-12-1060

PAK1 mediates resistance to PI3K inhibition in lymphomas. / Walsh, Katherine; McKinney, Matthew S.; Love, Cassandra; Liu, Qingquan; Fan, Alice; Patel, Amee; Smith, Jason; Beaven, Anne; Jima, Dereje D.; Dave, Sandeep S.

In: Clinical Cancer Research, Vol. 19, No. 5, 01.03.2013, p. 1106-1115.

Research output: Contribution to journalArticle

Walsh, K, McKinney, MS, Love, C, Liu, Q, Fan, A, Patel, A, Smith, J, Beaven, A, Jima, DD & Dave, SS 2013, 'PAK1 mediates resistance to PI3K inhibition in lymphomas', Clinical Cancer Research, vol. 19, no. 5, pp. 1106-1115. https://doi.org/10.1158/1078-0432.CCR-12-1060
Walsh, Katherine ; McKinney, Matthew S. ; Love, Cassandra ; Liu, Qingquan ; Fan, Alice ; Patel, Amee ; Smith, Jason ; Beaven, Anne ; Jima, Dereje D. ; Dave, Sandeep S. / PAK1 mediates resistance to PI3K inhibition in lymphomas. In: Clinical Cancer Research. 2013 ; Vol. 19, No. 5. pp. 1106-1115.
@article{13aed14cc9bf451496f0bce45ef6eaea,
title = "PAK1 mediates resistance to PI3K inhibition in lymphomas",
abstract = "Purpose: The phosphoinositide 3-kinase (PI3K) pathway is known to play an active role in many malignancies. The role of PI3K inhibition in the treatment of lymphomas has not been fully delineated. We sought to identify a role for therapeutic PI3K inhibition across a range of B-cell lymphomas. Experimental Design: We selected three small molecule inhibitors to test in a panel of 60 cell lines that comprised diverse lymphoma types. We tested the selective PI3K inhibitor BKM120 and the dual PI3K/ mTOR inhibitors BEZ235 and BGT226 in these cell lines. We applied gene expression profiling to better understand the molecular mechanisms associated with responsiveness to these drugs. Results: We found that higher expression of the PAK1 gene was significantly associated with resistance to all three PI3K inhibitors. Through RNA-interference-mediated knockdown of the PAK1 gene, we showed a dramatic increase in the sensitivity to PI3K inhibition. We further tested a small-molecule inhibitor of PAK1 and found significant synergy between PI3K and PAK1 inhibition. Conclusion: Thus, we show that PI3K inhibition is broadly effective in lymphomas and PAK1 is a key modulator of resistance to PI3K inhibition.",
author = "Katherine Walsh and McKinney, {Matthew S.} and Cassandra Love and Qingquan Liu and Alice Fan and Amee Patel and Jason Smith and Anne Beaven and Jima, {Dereje D.} and Dave, {Sandeep S.}",
year = "2013",
month = "3",
day = "1",
doi = "10.1158/1078-0432.CCR-12-1060",
language = "English (US)",
volume = "19",
pages = "1106--1115",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - PAK1 mediates resistance to PI3K inhibition in lymphomas

AU - Walsh, Katherine

AU - McKinney, Matthew S.

AU - Love, Cassandra

AU - Liu, Qingquan

AU - Fan, Alice

AU - Patel, Amee

AU - Smith, Jason

AU - Beaven, Anne

AU - Jima, Dereje D.

AU - Dave, Sandeep S.

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Purpose: The phosphoinositide 3-kinase (PI3K) pathway is known to play an active role in many malignancies. The role of PI3K inhibition in the treatment of lymphomas has not been fully delineated. We sought to identify a role for therapeutic PI3K inhibition across a range of B-cell lymphomas. Experimental Design: We selected three small molecule inhibitors to test in a panel of 60 cell lines that comprised diverse lymphoma types. We tested the selective PI3K inhibitor BKM120 and the dual PI3K/ mTOR inhibitors BEZ235 and BGT226 in these cell lines. We applied gene expression profiling to better understand the molecular mechanisms associated with responsiveness to these drugs. Results: We found that higher expression of the PAK1 gene was significantly associated with resistance to all three PI3K inhibitors. Through RNA-interference-mediated knockdown of the PAK1 gene, we showed a dramatic increase in the sensitivity to PI3K inhibition. We further tested a small-molecule inhibitor of PAK1 and found significant synergy between PI3K and PAK1 inhibition. Conclusion: Thus, we show that PI3K inhibition is broadly effective in lymphomas and PAK1 is a key modulator of resistance to PI3K inhibition.

AB - Purpose: The phosphoinositide 3-kinase (PI3K) pathway is known to play an active role in many malignancies. The role of PI3K inhibition in the treatment of lymphomas has not been fully delineated. We sought to identify a role for therapeutic PI3K inhibition across a range of B-cell lymphomas. Experimental Design: We selected three small molecule inhibitors to test in a panel of 60 cell lines that comprised diverse lymphoma types. We tested the selective PI3K inhibitor BKM120 and the dual PI3K/ mTOR inhibitors BEZ235 and BGT226 in these cell lines. We applied gene expression profiling to better understand the molecular mechanisms associated with responsiveness to these drugs. Results: We found that higher expression of the PAK1 gene was significantly associated with resistance to all three PI3K inhibitors. Through RNA-interference-mediated knockdown of the PAK1 gene, we showed a dramatic increase in the sensitivity to PI3K inhibition. We further tested a small-molecule inhibitor of PAK1 and found significant synergy between PI3K and PAK1 inhibition. Conclusion: Thus, we show that PI3K inhibition is broadly effective in lymphomas and PAK1 is a key modulator of resistance to PI3K inhibition.

UR - http://www.scopus.com/inward/record.url?scp=84874925474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874925474&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-1060

DO - 10.1158/1078-0432.CCR-12-1060

M3 - Article

C2 - 23300274

AN - SCOPUS:84874925474

VL - 19

SP - 1106

EP - 1115

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -